Mark Mueller, MD
Family Medicine · Lima, OHNPI 1063464923
Payments from drug & device makers
Across 394 payments — averaging $13.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$909
- AbbVie$763
- Lilly USA, LLC$552
- AstraZeneca$452
- Pfizer$384
- Amgen$236
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,450100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $909 |
| AbbVie(2 entities) | 66 | $763 |
| Lilly USA, LLC | 38 | $552 |
| AstraZeneca | 27 | $452 |
| Pfizer | 24 | $384 |
| Amgen | 17 | $236 |
| Merck | 11 | $173 |
| Boehringer Ingelheim | 10 | $171 |
| Novartis | 10 | $163 |
| Exact Sciences | 8 | $153 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $149 |
| GSK | 8 | $122 |
| Biohaven Pharmaceuticals, Inc. | 9 | $120 |
| Johnson & Johnson(2 entities) | 7 | $113 |
| Bayer | 6 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $89 |
| Dexcom, Inc. | 4 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $85 |
| Daiichi Sankyo Inc. | 4 | $68 |
| Astellas Pharma US Inc | 3 | $53 |
| Sunovion Pharmaceuticals Inc. | 4 | $50 |
| Kowa Pharmaceuticals America, Inc. | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $43 |
| Sumitomo Pharma America, Inc. | 3 | $41 |
| Corium, LLC | 2 | $34 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $31 |
| Lucid Diagnostics Inc. | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Eisai Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $12 |
How this compares
$5,465 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $158,678 |
| EliquisApixaban | 104 | $121,595 |
| TrulicityDulaglutide | 72 | $106,963 |
| MounjaroTirzepatide | 73 | $90,584 |
| FarxigaDapagliflozin Propanediol | 82 | $88,273 |
| JanuviaSitagliptin Phosphate | 54 | $73,292 |
| OzempicSemaglutide | 49 | $53,684 |
| RybelsusSemaglutide | 19 | $34,587 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 38 | $30,399 |
| XareltoRivaroxaban | 23 | $29,669 |
| JanumetSitagliptin Phos/Metformin Hcl | 16 | $25,295 |
| MyrbetriqMirabegron | 36 | $24,298 |
| Spiriva RespimatTiotropium Bromide | 28 | $19,338 |
| EntrestoSacubitril/Valsartan | 22 | $12,025 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 93 | $10,723 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $552 | $197,547145 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $171 | $184,823140 claims |
| PfizerEliquis, Premarin, Prempro | $384 | $131,154136 claims |
| MerckJanuvia, Janumet | $173 | $98,58770 claims |
| AstraZenecaFarxiga, Brilinta | $452 | $97,57693 claims |
| Novo NordiskOzempic, Rybelsus | $909 | $88,27168 claims |
| Johnson & JohnsonXarelto | $113 | $29,66923 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $24,29836 claims |
| NovartisEntresto | $163 | $12,02522 claims |
| GSKIncruse Ellipta | $122 | $6,52213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Lima
- David NeidhardtLima$248K
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.